Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126542121 | 12654212 | 1 | I | 20160810 | 0 | 20160815 | 20160815 | DIR | 35.00 | YR | M | N | 230.00000 | LBS | 20160812 | N | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126542121 | 12654212 | 1 | PS | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | N | Y | MR11664 | 20171130 | 0 | 1 | DF | CAPSULE | QD | |||
| 126542121 | 12654212 | 3 | C | GABBAPENTIN | 2 | 0 | |||||||||||||
| 126542121 | 12654212 | 5 | C | OMEGA 3 | OMEGA-3 FATTY ACIDS | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126542121 | 12654212 | 1 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126542121 | 12654212 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126542121 | 12654212 | Drug withdrawal syndrome | |
| 126542121 | 12654212 | Feeling abnormal | |
| 126542121 | 12654212 | Pain | |
| 126542121 | 12654212 | Pneumonia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126542121 | 12654212 | 1 | 7 | YR |